About Aligos Therapeutics, Inc.
https://www.aligos.comAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.
CEO
Lawrence M. Blatt MBA,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-19 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ALTITUDE CREST PARTNERS INC.
Shares:2.84M
Value:$25.74M
WOODLINE PARTNERS LP
Shares:468.2K
Value:$4.24M
DEEP TRACK CAPITAL, LP
Shares:444.11K
Value:$4.02M
Summary
Showing Top 3 of 40
About Aligos Therapeutics, Inc.
https://www.aligos.comAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $741K ▼ | $29.1M ▲ | $-31.54M ▼ | -4.26K% ▼ | $-3.04 ▼ | $-30.78M ▼ |
| Q2-2025 | $965K ▲ | $19.27M ▼ | $-15.86M ▼ | -1.64K% ▼ | $-1.53 ▼ | $-15.42M ▲ |
| Q1-2025 | $311K ▼ | $19.55M ▼ | $43.09M ▲ | 13.85K% ▲ | $5.12 ▲ | $-18.73M ▲ |
| Q4-2024 | $629K ▼ | $21.19M ▼ | $-82.15M ▼ | -13.06K% ▼ | $-13.08 ▼ | $-19.89M ▼ |
| Q3-2024 | $1.27M | $21.4M | $-19.26M | -1.52K% | $-3.07 | $-19.46M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $99.1M ▼ | $109.76M ▼ | $37.93M ▲ | $71.83M ▼ |
| Q2-2025 | $122.94M ▼ | $134.71M ▼ | $32.84M ▼ | $101.87M ▼ |
| Q1-2025 | $137.86M ▲ | $150.7M ▲ | $34.25M ▼ | $116.44M ▲ |
| Q4-2024 | $56.94M ▼ | $70.09M ▼ | $99.07M ▲ | $-28.97M ▼ |
| Q3-2024 | $74.92M | $88.43M | $38.33M | $50.1M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-31.54M ▼ | $-24.34M ▼ | $47.68M ▲ | $-53K ▲ | $23.29M ▲ | $-24.54M ▼ |
| Q2-2025 | $-15.86M ▼ | $-15.5M ▲ | $-39.42M ▲ | $-177K ▼ | $-55.1M ▼ | $-15.61M ▲ |
| Q1-2025 | $43.09M ▲ | $-20.91M ▼ | $-44.07M ▼ | $101.74M ▲ | $36.77M ▲ | $-20.95M ▼ |
| Q4-2024 | $-82.15M ▼ | $-18.4M ▲ | $19.97M ▲ | $97K ▲ | $1.67M ▲ | $-18.43M ▲ |
| Q3-2024 | $-19.26M | $-20.1M | $10.4M | $-4K | $-9.71M | $-20.13M |
CEO
Lawrence M. Blatt MBA,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-08-19 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ALTITUDE CREST PARTNERS INC.
Shares:2.84M
Value:$25.74M
WOODLINE PARTNERS LP
Shares:468.2K
Value:$4.24M
DEEP TRACK CAPITAL, LP
Shares:444.11K
Value:$4.02M
Summary
Showing Top 3 of 40